Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Biological age & clocks
Research brief

Epigenetic clocks: when to trust anti-aging intervention results

Extending single-clock studies to more clocks yielded no further significant results; the authors propose three criteria for trusting clock results and suggest some earlier single-clock findings be reexamined. [1]

Automatic summary · not editorially reviewed

The key findings

  1. Epigenetic clocks are potential biomarkers of aging associated with morbidity and mortality and are used as outcome measurements for anti-aging interventions. [1]

  2. Extending published single-clock intervention studies to additional clock models produced no additional clocks reaching statistical significance. [1]

  3. The authors propose three criteria for confidence and suggest some previously published single-clock findings may warrant reexamination. [1]

The source at a glance

Study type / format
Abstract of a methodological analysis with simulation and reanalysis of published studies
Population / context
Previously published single-clock intervention studies, positive control datasets of age-accelerating events, simulation data and longitudinal control datasets
Summary based on
Study abstract
Original publication
October 1, 2026

Why epigenetic clock results may disagree

Epigenetic clocks are described as potential biomarkers of aging because they are associated with illness and death, and they are increasingly used as outcome measurements in anti-aging interventions. As more new clocks appear, different clocks may not agree on an intervention's effect. This raises the question of when researchers can trust clock results.

Supporting source [1]

No extra significant clocks in extended analyses

The authors extended previously published single-clock intervention studies to include additional clock models. No additional clocks reached statistical significance. They then analyzed clock behavior across positive control datasets, meaning age-accelerating events, and proposed three criteria that increase confidence in a result: reliable positive-control-based clocks respond, mortality-trained or pace-of-aging clocks respond, and multiple clocks respond in the same direction.

Supporting source [1]

Simulations and examples behind the proposed framework

To explain why genuine effects would appear across multiple clocks, the authors ran a simulation study showing that reliable clocks are more sensitive to true effects. Using longitudinal control datasets, they showed that changes in reliable clocks are correlated with each other. They then gave examples of interventions that do satisfy the criteria. The authors present this as a framework for interpreting clock results and suggest some previously published single-clock findings may warrant reexamination.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. The abstract reports no sample sizes, follow-up durations or effect estimates, and the criteria are a proposed framework, not a validated standard. Associations do not establish that interventions slow human aging.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
When to Trust Epigenetic Clocks: Avoiding False Positives in Aging Interventions.

Borrus DS, Sehgal R, Armstrong JF, Kasamoto J, Gonzalez J, Higgins-Chen A. · europepmc.org · October 1, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    potential biomarkers of aging due to their
  2. Finding 2 ↑

    no additional clocks reach statistical significance
  3. Finding 3 ↑

    some previously published single-clock findings may warrant

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…